Novartis AG : Good timing to anticipate a continuation of the trend
Entry price | Target | Stop-loss | Potential |
---|
CHF 88.9 |
CHF 95.7 |
CHF 81.46 |
+7.65% |
---|
The current trading zone is interesting to the point that investors should pay attention to the stock and anticipate a return of the underlying upward trend.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● The company is one of the best yield companies with high dividend expectations.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● The stock is in a well-established, long-term rising trend above the technical support level at 82 CHF
Weaknesses● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● The company's enterprise value to sales, at 4.18 times its current sales, is high.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.